Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4022_Библиотеки_им_академика_М_И_Перельмана
.pdf
481
Литература
Dalen J.E. Trombolysis in submassive pulmonary embolism? No //
J. Thromb. Haemost. — 2003. — Vol. 1. — P. 1130–1132.
Dalen J.E. Pulmonary embolism: what have we learned since Virchow?
Na tural history, pathophysiology, and diagnosis // Chest. — 2002. —
Vol. 122. — P. 1440–1456.
Daly E., Vessey M.P., Hawkims W.W. et al. Risk of venous thromboem-
bolism in users of hormonal replacement therapy // Lancet. — 1996. —
Vol. 348. — P. 977–980.
De Moerloose P., Albenc-Geals M., Boeblen F. et al. Deep Venous throm-
bosis and thrombophilia: indication for testing and clinical implication //
Semin.Vasc. Med. — 2001. — Vol. 1 (1). — P. 89–96.
De Stefano V., Finazzi G., Mannucci P.M. Inherited thrombophilia:
pathogenesis, clinical syndromes, and management // Blood. — 1996. —
Vol. 87. — P. 3531–3544.
De Stefano V., Martinelli I., Mannucci P.M. et al. The risk of recurrent deep
venous thrombosis among heterozygous carriers of both factor V Leiden
and the G20210A prothrombin mutation // New Engl. J. Med. — 1999. —
Vol. 341. — P. 801–806.
De Vivo M.J., Krause J.S., Lammertse D.P. Recent trends in mortality and
causes of death among persons with spinal cord injury // Arch. Phys. Med.
Rehabil. — 1999. — Vol. 80. — P. 1411–1419.
Dearborn J.T., Hu S.S., Tribus C.B. et al. Thromboembolic complications after ma-
jor thoracolumbar spine surgery // Spine. — 1999. — Vol. 24. — P. 1471–1476.
Decousus H., Leizorovicz A., Parent F. et al. A clinical trial of vena caval filters
in the prevention of pulmonary embolism in patients with proximal deep-
vein thrombosis // New Engl. J. Med. — 1998. — Vol. 338. — P. 409–416.
Di Nisio M., Squizzato A., Rutjes A.W. et al. Diagnostic accuracy of D-dim-
er test for exclusion of venous thromboembolism: a systematic review //
J. Thromb. Haemost. — 2007. — Vol. 5. — P. 296–304.
Dickinson L.D., Miller L.D., Patel C.P. et al. Enoxaparin increases the in-
cidence of postoperative intracranial hemorrhage when initiated preop-
eratively for deep venous thrombosis prophylaxis in patients with brain
tumors // Neurosurgery. — 1998. — Vol. 43. — P. 1074–1081.
Dolovich L.R., Ginsberg J.S., Douketis J.D. et al. A meta-analysis comparing
low-molecular-weight heparins with unfractionated heparin in the treat-
ment of venous thromboembolism: examining some unanswered questions
regarding location of treatment, product type, and dosing frequency //
Arch. Intern. Med. — 2000. — Vol. 160. — P. 181–188.
Douketis J.D. Perioperative anticoagulation management in patients who
are receiving oral anticoagulant therapy: a practical guide for clinicians
//
Thromb. Res. — 2002. — Vol. 108 (1). — P. 3–13.
Douketis J.D., Gu C.S., Schulman S. et al. The risk for fatal pulmonary em-
bolism after discontinuing anticoagulant therapy for venous thromboem-
bolism // Ann. Intern. Med. — 2007. — Vol. 147. — P. 766–774.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
482
Литература
Douketis J.D., Leeuwenkamp O., Grobara P. et al. The incidence and prognostic
significance of elevated cardiac troponins in patients with submassive pulmo-
nary embolism // J. Thromb. Haemost. — 2005. — Vol. 3. — P. 508–513.
Dubuc-Lissoir J., Ehlen T., Heywood M. et al. Prevention and treatment
of thrombo-embolic disease in gynaecological surgery // J. Soc. Obstet.
Gynaecol. Can. — 1999. — Vol. 21. — P. 1087–1094.
Duller H.R., Van Doormaal F.F., Van Sluis G.L., Kamphuisen P.W. Cancer
and thrombosis: from molecular mechanisms to clinical presentations //
J. Thromb. Haemost. — 2007. — Vol. 5 (1). — P. 246–254.
Durieux P.S., Nizard R., Ravaud P. et al. A clinical decision support system
for prevention of VTE: effect on physician behavior // JAMA. — 2000. —
Vol. 283. — P. 2816–2821.
Ears J.P. Private practice decisions: case II: presumptoion of pulmonary
embolism // Medscape Radiology. — 2003. — Vol. 4 (1).
Eight-year follow-up of patients with permanent vena cava filters in the
prevention of pulmonary embolism: the PREPIC (Prevention du Risque
d’Embolie Pulmonaire par Interruption Cave) randomized study // Circu-
lation. — 2005. — Vol. 112. — P. 416–422.
Eikelboom J.W., Hirsh J. Bleeding and management of bleeding // European
Heart J. Supplements. — 2006. — Vol. 8. — G38–G45.
Enders J.M., Pharm D., Burke J.M. et al. Prevention of venois thromboembo-
lism in acute medical illness // Pharmacotherapy. — 2002. — Vol. 22 (12). —
P. 1564–1578.
ENOXACAN Study Group. Efficacy and safety of enoxaparin versus un-
fractionated heparin for prevention of deep vein thrombosis in elective can-
cer surgery: a double-blind randomized multicentre trial with venographic
assessment // Br. J. Surg. — 1997. — Vol. 84. — P. 1099–1103.
Eriksson B.I., Agnelli G., Cohen A.T. et al. Direct thrombin inhibitor
melagatran followed by oral ximelagatran in comparison with enoxaparin
for prevention of venous thromboembolism after total hip or total knee
replacement: the METHRO III study // Thromb. Haemost. — 2003. —
Vol. 89. — P. 288–296.
Eriksson B.I., Agnelli G., Cohen A.T. et al. The oral direct thrombin in-
hibitor ximelagatran, and its subcutaneous (sc) form melagatran, compared
with enoxaparin for prophylaxis of venous thromboembolism (VTE) in
total hip or total knee replacement (THR or TKR): the EXPRESS study
[abstr.] // Blood. — 2002. — Vol. 100. — 82a.
Eriksson B.I., Bauer K.A., Lassen M.R., Turpie A.G.G. Fondaparinux compared
with enoxaparin for the prevention of venous thromboembolism after hip-
fracture surgery // New Engl. J. Med. — 2001. — Vol. 345. — P. 1298–1304.
Eriksson B.I., Ekman S., Lindbratt S. et al. Prevention of thromboembolism
with use of recombinant hirudin: results of a double-blind, multicenter
trial comparing the efficacy of desirudin (Revasc) with that of unfraction-
ated heparin in patients having a total hip replacement // J. Bone Joint.
Surg. — 1997. — Vol. 79-A. — P. 326–333.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
483
Литература
Eriksson B.I., Lassen M.R. PENTasaccharide in HIp-FRActure Surgery
Plus (PENTHIFRA Plus) Invetigators. Duration of prophylaxis against
venous thromboembolism with fondaparinux after hip fracture surgery:
a multicenter, randomized, placebo-controlled, double-blind study // Arch.
Intern. Med. — 2003. — Vol. 163. — P. 1337–1342.
Eriksson B.I., Wille-Jorgensen P., Kalebo P. et al. A comparison of recom-
binant hirudin with a low-molecular-weight heparin to prevent throm-
boembolic complication after total hip replacement // New Engl. J. Med. —
1997. — Vol. 337. — P. 1329–1335.
Eschwe`ge V., Robert A. Strikes in French public transport and resistance
to activated protein C // Lancet. — 1996. — Vol. 347. — P. 206.
Esmon C.T. Protein C // Progress in Hemostasis and thrombosis / Ed.
T.S. Spaet. — Orlando: Grune and Stratton, 1984. — Vol. 7. — P. 25.
Esmon C.T., Schwarz H.P. An update on clinical and basic aspects of the
protein C anticoagulant pathway // Trends Cardiovasc. Med. — 1995. —
Vol. 5. — P. 141–148.
Etchells E., McLeod R.S., Geerts W. et al. Economic analysis of low-dose
heparin vs the low-molecular-weight heparin enoxaparin for prevention of
venous thromboembolism after colorectal surgery // Arch. Intern. Med. —
1999. — Vol. 159. — P. 1221–1228.
Failla P.J., Reed K.D., Summer W.R., Karam G.H. Inferior vena caval filters:
key considerations // Am. J. Med. Sci. — 2005. — Vol. 330. — P. 82–87.
Fair D.S., Marlar R.A., Levin E.G. Human endothelial cells synthesize pro-
tein S // Blood. — 1986. — Vol. 67. — P. 1168–1171.
Falanga A., Rickles F.R. Pathophysiology of the thrombophilic state in the
cancer patient // Semin. Thromb. Hemost. — 1999. — Vol. 25. — P. 173–182.
Fattahi O.H. Thrombolytic therapy for deep vein thrombosis and pulmo-
nary embolism // Sem. J. — 1999. — Vol. 2 (3). — P. 2–7.
Fay P.H., Smudzin T.M., Walker F.J. Activated protein C-catalyzed inacti-
vation of human factor VIII and factor VIIIa // J. Biol. Chem. — 1991. —
Vol. 6. — P. 20139–20145.
Fay P.J. Factor VIII structure and function // Тhromb. Haemost. —
1993. — Vol. 70. — P. 63–67.
Fedullo P.F., Auger W.R., Kerr K.M. et al. Chronic thromboembolic pulmonary
hypertension // New Engl. J. Med. — 2001. — Vol. 345. — P. 1465–1472.
Ferree B.A., Stern P.J., Jolson R.S. et al. Deep venous thrombosis after spinal
surgery // Spine. — 1993. — Vol. 18. — P. 315–319.
Fiessinger J.N.,
Huisman M.V., Davidson B.L. et al. THRIVE Treatment
Study Investigators: Ximelagatran vs low-molecular-weight heparin and
warfarin for the treatment of deep vein thrombosis: a randomized trial
//
JAMA. — 2005. — Feb. 9; 293 (6). — P. 681–689.
Finazzi G., Marchioli R., Brancaccio V. et al. A randomized clinical trial of high-
intensity warfarin vs. conventional antithrombotic therapy for the preven-
tion of recurrent thrombosis in patients with the antiphospholipid syndrome
(WAPS) // J. Thromb. Haemost. — 2005. — May; 3 (5). — P. 848–853.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
170.
484
Литература
Fisher B., Constantino J., Redmond C. et al. A randomized clinical trial
evaluating tamoxifen in the treatment of patients with mode-negative
breast cancer who have estrogen-receptor-positive tumors // New Engl. J.
Med. — 1989. — Vol. 320. — P. 479–484.
Fisher B., Constantino J.P., Wickerham D.L. et al. Tamoxifen for prevention
of breast cancer: report of the National Surgical Adjuvant Breast and Bowel
Project P-1 Study // J. Nat. Cancer Inst. — 1998. — Vol. 90. — P. 1371–1388.
Fisher B., Dignan J., Wolmark N. et al. Tamoxifen and chemotherapy for
lymph node-negative, estrogen receptor-positive breast cancer // J. Nat.
Cancer Inst. — 1997. — Vol. 89. — P. 1673–1682.
Fisher C.G., Blachut P.A., Salvain A.J. et al. Effectiveness of pneumatic leg
compression devices for the prevention of thromboembolic disease in ortho-
paedic trauma patients: a prospective, randomized study of compression alone
versus no prophylaxis // J. Orthop. Trauma. — 1995. — Vol. 9. — P. 1–7.
Fletcher J.P., Batiste P. Incidence of deep vein thrombosis following vascu-
lar surgery // Int. Angiol. — 1997. — Vol. 16. — P. 65–68.
Fletcher J.P., Koutts J., Ockelford P.A. Deep vein thrombosis prophylaxis:
a survey of current practice in Australia and New Zealand // Aust. N. Z. J.
Surg. — 1992. — Vol. 62. — P. 601–605.
Flinn W.R., Sandager G.P., Silva M.B. et al. Prospective surveillance for
perioperative venous thrombosis: experience in 2643 patients // Arch.
Surg. — 1996. — Vol. 131. — P. 472–480.
Flordal P.A., Bergqvist D., Burmark U.-S. et al. Risk factors for major
thromboembolism and bleeding tendency after elective general surgical
operations // Eur. J. Surg. — 1996. — Vol. 162. — P. 783–789.
Flordal P.A., Bergqvist D., Ljungstrom K.-G. et al. Clinical relevance of
the fibrinogen uptake test in patients undergoing general abdominal sur-
gery — relation to major thromboembolism and mortality // Thromb.
Res. — 1995. — Vol. 80. — P. 491–497.
Fraisse F., Holzapfel L., Couland J.-M. et al. Nadroparin in the prevention
of deep vein thrombosis in acute decompensated COPD // Am. J. Respir.
Crit. Care Med. — 2000. — Vol. 161. — P. 1109–1114.
Francis C.W., Marder W.J., Evarts C.M. et al. Two-step warfarin therapy:
prevention of postoperative thrombosis without excessive bleeding //
JAMA. — 1983. — Vol. 249. — P. 374–378.
Francis C.W.
, Pellegrini V.D., Leibert K.M. et al. Comparison of two war-
farin regimens in the prevention of venous thrombosis following total knee
replacement
// Thromb. Haemost. — 1996. — Vol. 75. — P. 706–711.
Francis C.W., Pellegrini V.D., Totterman S. et al. Prevention of deep-
vein thrombosis after total hip arthroplasty: comparison of warfarin and
dalteparin // J. Bone Joint. Surg. — 1997. — Vol. 79. — P. 1365–1372.
Francis R.M., Brenkel I.J. Survey of use of thromboprophylaxis for rou-
tine total hip replacement by British orthopaedic surgeons // Br. J. Hosp.
Med. — 1997. — Vol. 57. — P. 427–431.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
485
Литература
Franzeck U.K., Schalch I., Jager K.A. et al. Prospective 12-year follow-up study
of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk
patients (Zurich study) // Circulation. — 1996. — Vol. 93. — P. 74–79.
Fricker J.P., Vergnes Y., Schach R. et al. Low dose heparin versus low mo-
lecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of throm-
boembolic complications of abdominal oncological surgery // Eur. J. Clin.
Invest. — 1988. — Vol. 18. — P. 561–567.
Friedman R.J., Dunsworth G.A. Cost analyses of extended prophylaxis with
enoxaparin after hip arthroplasty // Clin. Orthop. — 2000. — Vol. 370. —
P. 171–182.
Galie N., Hoeper M.M., Humbert V. et al. Guidelines for the diagnosis and
treatment of pulmonary hypertension // Eur. Heart J. — 2009. — Vol. 30. —
P. 2493–2537.
Gallus A.S., Hirsh J., Tuttle R.J. et al. Small subcutaneous doses of heparin
in prevention of venous thrombosis // New Engl. J. Med. — 1973. —
Vol. 288. — P. 545–551.
Gallus A.S., Salzman E.W., Hirsh J. Prevention of Venous Thromboembo-
lism // In: Hemostasis and thrombosis: basic Principles and Clinical Prac-
tice / Eds. R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman. — 3
d
ed. —
Philadelphia: Lippincott, 1994. — P. 1331–1345.
Gandrille S., Borgel D., Sala N. et al. Protein S deficiency: a database of
mutations — summary of the first update // Thromb. Haemost. — 2000. —
Vol. 84. — P. 918.
Garcia de Frutos P., Alim R.I.M., Hardig Y. et al. Differential regulation
of alpha and beta chains of C4b-binding protein during acute-phase re-
sponse resulting in stable plasma levels of free anticoagulant protein S //
Blood. — 1994. — Vol. 84. — P. 815–822.
Gardlund B. Randomised, controlled trial of low-dose heparin for preven-
tion of fatal pulmonary embolism in patients with infectious diseases //
Lancet. — 1996. — Vol. 347. — P. 1357–1361.
Gari M., Kalkon L., Urrutia T. et al. The influence of low protein S plas-
ma levels in young women, on the definition of normal range // Thromb.
Res. — 1995. — Vol. 73. — P. 149–152.
Garlund B. Randomised, controlled trial of low-dose heparin for preven-
tion of fatal pulmonary embolism in patients with infectious diseases for
the Heparin Prophylaxis Study Group // Lancet. — 1996. — Vol. 347. —
P. 1357–1361.
Geerts W., Jay R., Code K. et al. Venous foot pump as thromboprophy-
laxis in major trauma [abstract] // Thromb. Haemost. — 1999. — Vol. 82
(Suppl.). — S. 650–651.
Geerts W.H., Bergqvist D., Pineo G.F. et al. Prevention of venous throm-
boembolism the 8
th
ACCP Conference on antithrombotic and thrombo-
lytictherapy // Chest. — 2008. — Vol. 133/6. — 381S–353S.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
486
Литература
Geerts W.H., Code K.I., Singer S. et al. Thromboprophylaxis after radi-
cal prostatectomy: a survey of Canadian urologists [abstract] // Thromb.
Haemost. — 1997. — Vol. 77 (Suppl.). — S. 124.
Geerts W.H., Jay R.M., Code K.I. et al. A comparison of low-dose heparin with
low-molecular-weight heparin as prophylaxis against venous thromboembolism
after major trauma // New Engl. J. Med. — 1996. — Vol. 335. — P. 701–707.
Gerhardt A., Scharf R.E., Zotz R.B. Effect of hemostatic risk factors on the
individual probability of thrombosis during pregnancy and the puerper-
ium // Thromb. Haemost. — 2003. — Vol. 90 (1). — P. 77–85.
Gillies T.E., Ruckley C.V., Nixon S.J. Still missing the boat with fatal pul-
monary embolism // Br. J. Surg. — 1996. — Vol. 83. — P. 1394–1395.
Ginsberg J.S., Bates S.M. Management of venous thromboembolism during
pregnancy // J. Thromb. Haemost. — 2003. — Vol. 1. — P. 1435–1442.
Ginsberg J.S., Gent M., Turkstra F. et al. Postthrombotic syndrome after
hip or knee arthroplasty: a cross-sectional study // Arch. Intern. Med. —
2000. — Vol. 160. — P. 669–672.
Ginsberg J.S., Hirsh J., Julian J. et al. Prevention and treatment of postphle-
bitic syndrome: results of a 3-part study // Arch. Intern. Med. — 2001. —
Vol. 161. — P. 2105–2109.
Girolami B., Prandoni P., Stefani P.M. et al. The incidence of heparin-in-
duced thrombocytopenia in hospitalized medical patients treated with sub-
cutaneous unfractionated heparin: a prospective cohort study // Blood. —
2003. — Vol. 101. — P. 2955–2959.
Glynn R.J., Rosner B. Comparison of risk factors for the competing risks
of coronary heart disease, stroke and venous thromboembolism // Am. J.
Epidemiol. — 2005. — Vol. 162. — P. 975–982.
Goldberg S.K., Lippmann M.L., Walkenstein M.D. et al. The prevalence of
DVT among patients in respiratory failure: the role of DVT prophylaxis
[abstract] // Am. J. Respir. Crit. Care Med. — 1996. — Vol. 153. — A94.
Goldhaber S.Z, Visani L., De Rosse M. Acute pulmonary embolism: clinical
outcomes in the Internatuional Cooperative Pulmonary Embolism Registry
(ICOPER) // Lancеt. — 1997. — Vol. 11. — P. 209–217.
Goldhaber S.Z. Echocardiography in the Management of pulmonary embo-
lism // Ann. Intern. Med. — 2002. — Vol. 136. — P. 691–700.
Goldhaber S.Z. Thrombolysis of pulmonary embolism // NEJM. — 2002. —
Vol. 347 (10); 15. — P. 1131–1132.
Goldhaber S.Z. Thrombosis in pulmonary embolism: a debatable indica-
tion // Thromb. Haemost. — 2001. — Vol. 86. — P. 444–451.
Goldhaber S.Z., Yaire W.D., Feldstein M.L. et al. Alteplase versus hparin in acute
pulmonary embolism. randomized trial assessing right-ventricular function
and pulmonary embolism // Lancet. — 1993. — Vol. 341. — P. 507–511.
Gomez C.R., Sandhu J., Mehla P. Resumption of anlicoagulation during
hypertensive cerebral hemorrhage with prosthetic heart valve [letter] //
Stroke. — 1988. — Vol. 19. — P. 407.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
211.
212.
213.
487
Литература
Goodman L.R., Stein P.D., Matta F. et al. CT venography and compression
sonography are diagnostically equivalent: data from PIOPED II // Am. J.
Roentgenol. — 2007. — Vol. 189. — P. 1071–1076.
Gorin L., Fauchier L., Nonin E. еt al. Antithrombotic treatment and the
risk of death and stroke in patients with atrial fibrillation and a CHADS2
score = 1 // Thromb. Haemost. — 2009. — Vol. 103. — P. 833–840.
Greenfield L.J., Proctor M.C. Suprarenal filter placement // J. Vasc.
Surg. — 1998. — Vol. 28. — P. 432–438.
Greer I.A., Nelson-Piercy C. Low molecular weight heparins for thrombo-
prophylaxis and threatment of venous thromboembolism in pregnancy:
a systematic review of safety andefficacy // Blood. — 2005. — Vol. 106. —
P. 401–407.
Greinacher A., Volpel H., Janssens U. et al. Recombinant hirudin (leperu-
din) provides safe and effective anticoagulation in patients with heparin-in-
duced thrombocytopenia // Circulation. — 1999. — Vol. 99. — P. 73–80.
Grifoni S., Olivvotto I., Cecchini P. et al. Short-term clinical outcome
of patients with acute pulmonary embolism, normal blood pressure, and
echocardiogrphic right ventricular dysfunction // Circulation. — 2000. —
Vol. 101. — P. 2817–2822.
Grodstein F., Stampfer M.J., Goldhaber S.Z. et al. Prospective study of
exogenous and risk of pulmonary embolism in women // Lancet. — 1996. —
Vol. 348. — P. 983–987.
Gruel Y., Pouplard C., Nguyen P., Borg J.Y. et al. Biological and clinical
features of lowmolecularweight heparin-induced thrombocytopenia // Br.
J. Haematol. — 2003. — Vol. 121. — P. 786–792.
Guant G.H., Akl E.A., Growther M., Gutterman D. et al. Antithrombotic
therapy and prevention of thrombosis 9
th
ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Ececutive summa-
ry // Chest. — 2012. — Vol. 141 (2) (Suppl.). — 17S–47S.
Haas S., Flosbach C.W. Antithromboembolic efficacy and safety of enoxaparin
in general surgery // Eur. J. Surg. — 1994. — Vol. 571 (Suppl.). — S. 37–43.
Haas S.B., Insall J.N., Scuderi G.R. et al. Pneumatic sequential-compression
boots compared with aspirin prophylaxis of deep-vein thrombosis after total
knee arthroplasty // J. Bone Joint. Surg. Am. — 1990. — Vol. 72. — P. 27–31.
Hackeng T.M., Van’t Veer C., Meijers J.C.M. et. al. Human protein S inhibits
prothrombinase complex activity on endothelial cells and platelets via direct
interaction with factors Va and Xa // J. Biol. Chem. — 1994. — Vol. 269. —
P. 21051–21058.
Hamel E., Pacouret G., Vincentelli D. et al. Thrombolysis or heparine therapy
in massive pulmonary embolism with right ventricular dilation: results from
a 128-patient monocentral registr // Chest. — 2001. — Vol. 120. — P. 120–125.
Hammers L.W., Cohn S.M., Brown J.M. et al. Doppler color flow ima-
ging surveillance of deep vein thrombosis in high-risk trauma patients //
J. Ultrasound. Med. — 1996. — Vol. 15. — P. 19–24.
214.
215.
216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
227.
488
Литература
Hansson P.-O., Eriksson H., Welin L. et al. Smoking and abdominal obesity:
risk factors for venous thromboembolism among middle-aged men: «The
Study of Men Born in 1913» // Arch. Intern. Med. — 1999. — Vol. 159. —
P. 1886–1890.
Hansson P.-O., Welin L., Tibblin G. et al. Deep vein thrombosis and pul-
monary embolism in the general population: «The study of men born in
1913» // Arch. Intern. Med. — 1997. — Vol. 157. — P. 1665–1670.
Harenberg J., Jorg I., Weiss C. Observations of alanine aminotransferase and
aspartate aminotransferase in THRIVE studies treated orally with ximelagat-
ran // Int. J. Toxicol. — 2006. — May-Jun.; 25 (3). — P. 165–169.
Harenberg J., Roebruck P., Heene D. et al. Subcutaneous low-molecular-
weight heparin versus standard heparin and the prevention of thromboembo-
lism in medical inpatients // Haemostasis. — 1996. — Vol. 26. — P. 127–139.
Harris K.W., Esmon C.T. Protein C is required for bovine platelets to sup-
port activated protein C binding and activity // J. Biol. Chem. — 1985. —
Vol. 260. — P. 2007–2010.
Harris S., Chen D., Green D. Enoxaparin for thromboembolism prophylaxis
in spinal injury: preliminary report on experience with 105 patients // Am.
J. Phys. Med. Rehabil. — 1996. — Vol. 75. — P. 326–327.
Hauch O., Khattar S.C., Jorgensen L.N. Cost-benefit analysis of prophylaxis
against deep vein thrombosis in surgery // Semin. Thromb. Hemost. —
1991. — Vol. 17 (Suppl. 3). — S. 280–283.
Hawkins D.W., Langley P.C., Kreuger K.P. A pharmacoeconomic assess-
ment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis
in patients undergoing knee replacement surgery // Clin. Ther. — 1998. —
Vol. 20. — P. 182–195.
Headrick J.R., Barker D.E., Pate L.M. et al. The role of ultrasonography
and inferior vena cava filter placement in high-risk trauma patients // Am.
Surg. — 1997. — Vol. 63. — P. 1–8.
Heaton D., Pearce M. Low molecular weight versus unfractionated heparin:
a clinical and economic appraisal // Pharmacoeconomics. — 1995. —
Vol. 8. — P. 91–99.
Heeb M.J., Espana F., Griffin J.H. Inhibition and complex-action of ac-
tivated protein C by two major inhibitors in plasma // Blood. — 1989. —
Vol. 73. — P. 446–454.
Heeb M.J., Paganini-Hill A., Griffin J.H., Fisher M. Low protein Z levels
and risk of ischemic stroke: differences by diabetic status and gender //
Blood. Cells. Mol. Dis. — 2002. — Sep.-Oct.; 29(2). — P. 139–144.
Heeb M.J., Rosing J., Bakker H.M. et. al. Protein S binds to and inhibits factor
Xa
// Proc. Natl. Acad. Sci. USA. — 1994. — Vol. 91. — P. 2728–2732.
Hefley W.F., Nelson C.L., Puskarich-May C.L. Effect of delayed admission
to the hospital on the preoperative prevalence of deep-vein thrombosis as-
sociated with fractures about the hip // J. Bone Joint. Surg. Am. — 1996. —
Vol. 78. — P. 581–583.
228.
229.
230.
231.
232.
233.
234.
235.
236.
237.
238.
239.
240.
241.
489
Литература
Heilmann L., Von Tempelhoff G.-F., Kirkpatrick C. et al. Comparison of
unfractionated versus low molecular weight heparin for deep vein throm-
bosis prophylaxis during breast and pelvic cancer surgery: efficacy, safe-
ty, and follow-up // Clin. Appl. Thromb. Hemost. — 1998. — Vol. 4. —
P. 68–73.
Heinzer H., Hammerer P., Graefen M. et al. Thromboembolic complica-
tion rate after radical retropubic prostatectomy: impact of routine ultra-
sonography for the detection of pelvic lymphoceles and hematomas // Eur.
Urol. — 1998. — Vol. 33. — P. 86–90.
Heit J.A. Thrombophillia: common questions on laboratory asessment and
management. American Society of Hematology Education program Bock //
Hematology. — 2007. — P. 127–135.
Heit J.A., Berkowitz S.D., Bona R. et al. Efficacy and safety of low molecular
heparin (ardeparin sodium) compared to warfarin for prevention of venous
thromboembolism following total knee replacement. A double blind dose-
randing study // Thromb. Haemost. — 1997. — Vol. 77. — P. 32–38.
Heit J.A., Mohr D.N., Silverstein M.D. et al. Predictor of recurrence after
deep vein thrombosis and pulmonary embolism: a population-based cohort
study // Arch. Intern. Med. — 2000. — Vol. 160. — P. 761–768.
Heit J.A., O’Fallon W.M., Petterson T.M. et al. Relative impact of risk fac-
tors for deep vein thrombosis and pulmonary embolism: a population-based
study // Arch. Intern. Med. — 2002. — Vol. 162. — P. 1245–1248.
Heit J.A., Silverstein M.D., Mohr D.N. et al. Risk factors for deep vein
thrombosis and pulmonary embolism: a population-based case-control
study // Arch. Intern. Med. — 2000. — Vol. 160. — P. 809–815.
Hingorani A., Ascher E., Ward M. et al. Combined upper and lower extremity
deep venous thrombosis // Cardiovasc. Surg. — 2001. — Vol. 9. — P. 472–477.
Hirsh J. Guidelines for antithrombotic threpy. — London: BC Decker Inc
Hamilton, 2005. — P. 121.
Hirsh J., Kearon C., Ginsberg J. Duration of anticoagulant therapy after first
episode of venous thrombosis in patients with inherited thrombophilia //
Arch. Intern. Med. — 1996. — Vol. 157. — P. 2174–2177.
Hirsh J., Warkenlin T.E., Shaughncssy S.G. et al. Heparin and low-molecu-
lar-weight heparin: mechanism of action, pharmacokinetics, dosing, moni-
toring, efficacy, and safety // Chest. — 2001. — Vol. 119. — 64S–94S.
Hirsh J., Warkentin T.E., Raschke R. et al. Heparin and low-molecular-weight
heparin: mechanisms of action, pharmacokinetics, dosing considerations,
monitoring, efficacy, and safety // Chest. — 1998. — Vol. 114 (Suppl.). —
489S–510S.
Hjelmstedt A., Bergvall U. Incidence of thrombosis in patients with tibial
fractures: a phlebographic study // Acta Chir. Scand. — 1968. — Vol. 134. —
P. 209–218.
Hoeper M.M., Mayer E., Simonneau G., Rubin L.J. Chronic thromboembolic
pulmonary hypertension // Circulation. — 2006. — Vol. 113. — P. 2011–2020.
242.
243.
244.
245.
246.
247.
248.
249.
250.
251.
252.
253.
254.
255.
490
Литература
Horlocker T.T., Heit J.A. Low molecular weight heparin: biochemistry, phar-
macology, perioperative prophylaxis regimens, and guidelines for regional
anesthetic management // Anesth. Analg. — 1997. — Vol. 85. — P. 874–885.
Horlocker T.T., Wedel D.J. Neuraxial block and low-molecular-weight
heparin: balancing perioperative analgesia and thromboprophylaxis // Reg.
Anesth. — 1998. — Vol. 2. — P. 164–177.
Howell M.D., Geraci J.M., Knowlton A.A. Congestive heart failure and
outpatient risk of venous thromboembolism: a retrospective, case-control
study // J. Clin. Epidemiol. — 2001. — Vol. 54. — P. 810–816.
Hron G., Eichinger S., Weltermann A. et al. Family history for imboembo-
lism and the risk for recurrence // Am. J. — Vol. 119. — P. 50–53.
Hui A.C.W., Heras-Palou C., Dunn I. et al. Graded compression stockings
for prevention of deep-vein thrombosis after hip and knee replacement //
J. Bone Joint. Surg. Br. — 1996. — Vol. 78. — P. 550–554.
Huisman M.V. On behalf of the THRIVE Treatment Study Investigators. Ef-
ficacy and safety of the oral direct thrombin inhibitor ximelagatran for acute
deep vein thrombosis with or without pulmonary embolism. Program and
abstracts of the XIX Congress of the International Society on Thrombosis
and Haemostasis. Birmingham, UK, July 12–18, 2003. — Abstract OC003.
Huisman M.V., Bounameaux H. Treating patients with venous thromboem-
bolism: initial strategies and long-term secondary prevention // Semin.
Vasc. Med. — 2005. — Aug.; 5 (3). — P. 276–284.
Huk M., Lynsky D., O’Callaghan T. et al. Compliance of sequential com-
pression device for deep vein thrombosis prophylaxis in the adult trauma
patient: surgical intensive care unit vs intermediate care [abstract] // Crit.
Care Med. — 1998. — Vol. 26 (Suppl.). — A47.
Hull R., Delmore T., Carter C. et al. Adjusted subcutaneous heparin versus
warfarin sodium in the long-term treatment of venous thrombosis // New
Engl. J. Med. — 1982. — Vol. 306. — P. 189–194.
Hull R., Hirsh J., Jay R. et al. Different intensities of oral anticoagulant
therapy in the treatment of proximal-vein thrombosis // New Engl. J.
Med. — 1982. — Vol. 307. — P. 1676–1681.
Hull R.D., Brant R.F., Pineo G.F. et al. Preoperative vs postoperative initia-
tion of low molecular weight heparin prophylaxis against VTE in patients
undergoing elective hip replacement // Arch. Intern. Med. — 1999. —
Vol. 159. — P. 137–141.
Hull R.D., Delmore T., Genton E. et al. Warfarin sodium versus low-dose
heparin in the long-term treatment of venous thrombosis // New Engl. J.
Med. — 1979. — Vol. 301. — P. 855–858.
Hull R.D., Hirsh J., Carter C.J., Jay R.M. et al. Pulmonary angiography,
ventilation lung scanning and venography for clinically suspected pulmo-
nary embolism with abnormal perfusion lung // Ann. Inter. Med. — 1983. —
Vol. 263. — P. 2753–2759.
Hull R.D., Pineo G.F., Francis C.W. et al.
Low-molecular-weight heparin
prophylaxis using dalteparin extended out-of-hospital warfarin versus out-
256.
257.
258.
259.
260.
261.
262.
263.
264.
265.
266.
267.
268.
269.
Соседние файлы в папке Библиотека им академика М.И. Перельмана